Genmab — Juni 2022
-
Video - A Promising Future for Treating Multiple Myeloma with Bispecific Antibodies https://www.proinvestor.com/boards/104195
-
Meget begejstrede forskerkommentarer om de bispecifikkei i videoen til slut ( fra 56-57 min) .
-
God morgen.
-
En stor tak til alle jer som tålmodigt bidrager med stort og småt/seriøst og sjovt i debat og chats, https://www.proinvestor.com/boards/104204/
-
New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta
(ofatumumab) had no evidence of disease activity (NEDA-3) https://www.novartis.com/news/media-releases/new-novartis-extension-phase-data-show-nearly-80-rms-patients-treated-kesimpta-ofatumumab-had-no-evidence-disease-activity-neda-3 -
Transactions in connection with share buy-back program https://ir.genmab.com/news-releases/news-release-details/transactions-connection-share-buy-back-program-17
-
Thanks E L.
-
God morgen.
-
God morgen. Nyt STÆRKT TA købssignal. Bullish udvikling op mod 2661 modstandsområdet. 85% sandsynlighed. https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/104233_Skaermbillede_2022_06_28_134152_2661.jpg
-
Biotech Stocks Facing FDA Decision In July 2022 https://www.proinvestor.com/investornyt/843364/biotech-stocks-facing-fda-decision-in-july-2022
-
Aktier/middag: SAS i hopla efter norsk tilsagn - medicinal tynger C25
https://www.proinvestor.com/investornyt/843378/aktier-middag-sas-i-hopla-efter-norsk-tilsagn-medicinal-tynger-c25
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind